Zeria Pharmaceutical Co., Ltd.

TSE:4559 Stock Report

Market Cap: JP¥99.3b

Zeria Pharmaceutical Management

Management criteria checks 2/4

Zeria Pharmaceutical's CEO is Sachiaki Ibe, appointed in Jun 2014, has a tenure of 10.75 years. directly owns 3.61% of the company’s shares, worth ¥3.59B. The average tenure of the management team and the board of directors is 2.8 years and 6.7 years respectively.

Key information

Sachiaki Ibe

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure10.8yrs
CEO ownership3.6%
Management average tenure2.8yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

Zeria Pharmaceutical's (TSE:4559) Dividend Will Be ¥23.00

Feb 24
Zeria Pharmaceutical's (TSE:4559) Dividend Will Be ¥23.00

Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Feb 10
Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00

Jan 17
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00

Jan 03
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00

Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Dec 17
Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00

Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00

Dec 03
Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00

Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

May 21
Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality

Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

Mar 15
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00

CEO

Sachiaki Ibe (83 yo)

10.8yrs

Tenure

Mr. Sachiaki Ibe serves as the Chief Executive Officer and Chairman at Zeria Pharmaceutical Co., Ltd since June 2014 and served as its President since April 1982. Mr. Ibe served as Managing Director of Zer...


Leadership Team

NamePositionTenureCompensationOwnership
Sachiaki Ibe
Chairman & CEO10.8yrsno data3.61%
¥ 3.6b
Mitsuhiro Ibe
President10.8yrsno data0.19%
¥ 187.0m
Yasuhisa Tanaka
Executive Officer and GM of Finance & Accounting Divisionno datano datano data
Yoshihiro Hiraga
Executive Officer and GM of Research & Development Headquarters11.8yrsno datano data
Hiroki Kato
Managing Executive Officer and GM of Asian Business2.8yrsno datano data
Toshiaki Kawagoe
Executive Officer and GM of Reliability Assurance Headquarters & Customer Relations Officeno datano datano data
Kenji Kusano
Executive Officer & GM of Consumer Healthcare Sales Division2.8yrsno datano data
Yuuki Okazawa
Managing Executive Officer & Director2.8yrsno data0.023%
¥ 22.5m
Mitsuru Iwai
Executive Officer & GM of Production & Logistics Headquarters2.8yrsno datano data
Kazuhiro Akiba
Executive Officer & GM of Pharmaceutical Sales Division2.8yrsno datano data
Kenichi Suzuki
Executive Officer and GM of Corporate Planning Division & Corporate Strategy Promotion Division2.5yrsno datano data
Masakazu Sakurai
Executive Officer & Head of European Business Headquarters2.2yrsno datano data

2.8yrs

Average Tenure

61yo

Average Age

Experienced Management: 4559's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Sachiaki Ibe
Chairman & CEO53yrsno data3.61%
¥ 3.6b
Mitsuhiro Ibe
President14.8yrsno data0.19%
¥ 187.0m
Yuuki Okazawa
Managing Executive Officer & Director1.8yrsno data0.023%
¥ 22.5m
Tetsuo Komori
Independent External Director9.8yrsno data0.016%
¥ 15.8m
Hirokazu Endo
Full-Time Audit & Supervisory Board Member1.8yrsno data0.18%
¥ 180.2m
Yukiko Naka
Outside Audit & Supervisory Board Member21.8yrsno data0.016%
¥ 15.8m
Kikuo Nomoto
Independent External Director7.7yrsno datano data
Masaru Kamisuki
Outside Audit & Supervisory Board Member5.8yrsno data0.0023%
¥ 2.3m
Seiji Morimoto
Independent External Director4.8yrsno data0.0023%
¥ 2.3m
Hiroyuki Kuroda
Full-time Audit & Supervisory Board Memberless than a yearno data0.0023%
¥ 2.3m

6.7yrs

Average Tenure

65yo

Average Age

Experienced Board: 4559's board of directors are considered experienced (6.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 07:51
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zeria Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Takashi AkahaneTokai Tokyo Intelligence Laboratory Co., Ltd.
Jayaprabha DhavaleVirtua Research Inc.